In last trading session, Atyr Pharma Inc (NASDAQ:ATYR) saw 3.76 million shares changing hands with its beta currently measuring 0.99. Company’s recent per share price level of $4.25 trading at $0.46 or 12.14% at ring of the bell on the day assigns it a market valuation of $356.75M. That closing price of ATYR’s stock is at a premium of 0.71% from its 52-week high price of $4.22 and is indicating a premium of 66.59% from its 52-week low price of $1.42.

Atyr Pharma Inc (NASDAQ:ATYR) trade information

Upright in the green during last session for gaining 12.14%, in the last five days ATYR remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $4.25 price level, adding 0.7% to its value on the day. Atyr Pharma Inc’s shares saw a change of 17.40% in year-to-date performance and have moved 14.56% in past 5-day. Atyr Pharma Inc (NASDAQ:ATYR) showed a performance of 17.73% in past 30-days.

Atyr Pharma Inc (ATYR) estimates and forecasts

This year revenue growth is estimated to fall -53.05% from the last financial year’s standing.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 43.36% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 3.09% while estimates for its earnings growth in next 5 years are of 8.29%.

On the other hand, Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 7.85 shares of worth $33.36 million or 9.35% of the total outstanding shares. The later fund manager was in possession of 6.62 shares on Oct 31, 2024 , making its stake of worth around $28.14 million in the company or a holder of 7.89% of company’s stock.